TRENTON, N.J. - Shareholders of drug maker Wyeth voted overwhelmingly yesterday to be bought by industry giant Pfizer Inc. More than 98 percent of Wyeth stockholders voted for the $68 billion acquisition.
The deal transforms New York-based Pfizer from being primarily a maker of blockbuster pills to a one-stop shop for medical treatments. That is because Wyeth, the number 12 drug maker, brings multibillion-dollar products and substantial expertise in creating and manufacturing biologic drugs, vaccines, nonprescription medicines, and animal health products.
